Silence Therapeutics PLC Result of General Meeting (9809Q)

TIDMSLN

RNS Number : 9809Q

Silence Therapeutics PLC

01 November 2021

Results of General Meeting

1 November 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general meeting held today, 1 November 2021, all resolutions set out in the notice of meeting were duly passed on a poll.

The votes were as follows:

 
 Special Resolution          Votes        %       Votes      %      Votes        % of     Votes 
                              for                  against           total        ISC      withheld 
                                                                                  voted 
 1 - Approve the 
  cancellation of 
  the admission 
  to trading on 
  AIM of the ordinary 
  shares of nominal 
  value GBP0.05 
  each in the capital 
  of the Company 
  and authorise 
  the directors 
  of the Company 
  to take all action 
  reasonable or 
  necessary to effect 
  such cancellation          31,092,066   99.47   166,904    0.53   31,258,970   34.82    4,408,363 
                            -----------  ------  ---------  -----  -----------  -------  ---------- 
 2 - Approve, conditional 
  on the passing 
  of Resolution 
  1, the amendment 
  to the articles 
  of association 
  of the Company             31,354,885   99.89   34,007     0.11   31,388,892   35.00    4,278,441 
                            -----------  ------  ---------  -----  -----------  -------  ---------- 
 

The number of the Company's ordinary shares in issue as at the date of the meeting was 89,784,720 ordinary shares of nominal value GBP0.05 each.

A vote withheld is not a vote in law and has not been counted in the total votes or the calculation of the proportion of votes for and against the resolutions.

The Company confirms that, as at today's date, the timetable for the cancellation of the admission to trading on AIM of the Company's ordinary shares is as follows:

 
 Last date for receipt by Link Group               3 November 2021 at 1.00 
  from certificated shareholders of duly                              p.m. 
  completed block transfer participation 
  request forms and original share certificates 
 
 Last date for receipt by The Bank of             17 November 2021 at 3.00 
  New York Mellon from CREST holders of                               p.m. 
  duly completed issuance forms 
 
 Expected date of issuance of ADSs to                     24 November 2021 
  block transfer participants 
 
 Expected date of posting of ADS confirmations            24 November 2021 
  to shareholders by The Bank of New York 
  Mellon 
 
 Last day of dealings in the Ordinary                     29 November 2021 
  Shares on AIM 
 
 Cancellation of admission to trading             30 November 2021 at 7.00 
  on AIM of the Ordinary Shares                                       a.m. 
-----------------------------------------------  ------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                              Tel: [phone] 
  Gem Hopkins, Head of IR & Corporate Communications 
  Investec Bank plc (Nominated Adviser and              Tel: +44 (0) 20 
   Broker)                                               7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                           Tel: +44 (0) 20 
  Consilium Strategic Communications                    3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMDFLFBFFLLFBK

(END) Dow Jones Newswires

November 01, 2021 13:33 ET (17:33 GMT)